
    
      A multi-center, open-label, single arm study to evaluate the safety and the effect of
      ALLN-177 to reduce urinary oxalate excretion in recurrent kidney stone formers with
      associated hyperoxaluria. The study design includes a screening period to confirm
      eligibility, followed by a 3-day baseline period, 4-day open label treatment period with
      ALLN-177 and 4-day follow up period.
    
  